Catalent reports Q2 adjusted EPS 67c, consensus 69c

Reports Q2 revenue $1.15B, consensus $1.12B. "We are well positioned to leverage the diverse investments we have made across our portfolio to support sustainable, long-term, and profitable growth," commented CEO Alessandro Maselli. "Notably, our extended partnership with Moderna, a pioneer in mRNA technology, and our recently expanded partnership with Sarepta, a leader in gene therapy, build on our long experience with customers in these growth areas. These partnerships underscore the importance we place on our long-term trusted relationships. In addition, we are improving efficiency with the restructuring actions that we have executed recently, and we are bringing a renewed focus on efficiency across our organization as a whole."